Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Stanford University500 enrolled

Overview

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

500

Conditions

Lymphoma, Non-Hodgkin Lymphomas: Non-Hodgkin Lymphomas: Non-Hodgkin Cutaneous Lymphoma Lymphomas: Non-Hodgkin Diffuse Large B-Cell Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell Lymphomas: Non-Hodgkin Mantle Cell

Outcomes

Primary Outcomes

To characterize the molecular and cell biology of the tumor cells in lymphoma.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes